{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:40:15Z","timestamp":1793227215241,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"crossref","award":["FDM202206015346"],"award-info":[{"award-number":["FDM202206015346"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Groupement d\u2019int\u00e9r\u00eat scientifique - Centre fran\u00e7ais pour les 3R","award":["22FC3R-018"],"award-info":[{"award-number":["22FC3R-018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40262-025-01574-5","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:12:04Z","timestamp":1758978724000},"page":"1843-1854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3141-5925","authenticated-orcid":false,"given":"Laure-H\u00e9l\u00e8ne","family":"Pr\u00e9ta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efm","family":"Bouazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantz","family":"Foissac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Froelicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efk","family":"Urien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Buth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tr\u00e9luyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"1574_CR1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/01.AOG.0000116689.75396.5f","volume":"103","author":"HA Bennett","year":"2004","unstructured":"Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103:698\u2013709.","journal-title":"Obstet Gynecol"},{"key":"1574_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/bcp.12849","volume":"81","author":"A B\u00e9rard","year":"2016","unstructured":"B\u00e9rard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao J-P. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81:589\u2013604.","journal-title":"Br J Clin Pharmacol"},{"key":"1574_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.earlhumdev.2012.01.014","volume":"88","author":"G Ibanez","year":"2012","unstructured":"Ibanez G, Charles M-A, Forhan A, Magnin G, Thiebaugeorges O, Kaminski M, et al. Depression and anxiety in women during pregnancy and neonatal outcome: data from the EDEN mother-child cohort. Early Hum Dev. 2012;88:643\u20139.","journal-title":"Early Hum Dev"},{"key":"1574_CR4","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/bcp.13608","volume":"84","author":"A B\u00e9nard-Laribi\u00e8re","year":"2018","unstructured":"B\u00e9nard-Laribi\u00e8re A, Pambrun E, Sutter-Dallay A-L, Gautier S, Hurault-Delarue C, Damase-Michel C, et al. Patterns of antidepressant use during pregnancy: a nationwide population-based cohort study: patterns of antidepressant use in pregnancy. Br J Clin Pharmacol. 2018;84:1764\u201375.","journal-title":"Br J Clin Pharmacol"},{"key":"1574_CR5","doi-asserted-by":"publisher","first-page":"544.e1","DOI":"10.1016\/j.ajog.2007.01.033","volume":"196","author":"WO Cooper","year":"2007","unstructured":"Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007;196:544.e1-544.e5.","journal-title":"Am J Obstet Gynecol"},{"key":"1574_CR6","doi-asserted-by":"crossref","unstructured":"Treatment and management of mental health conditions during pregnancy and postpartum: ACOG clinical practice guideline no. 5. Obst Gynecol. 2023;141:1262\u201388.","DOI":"10.1097\/AOG.0000000000005202"},{"key":"1574_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/0004867418762057","volume":"52","author":"NM Molenaar","year":"2018","unstructured":"Molenaar NM, Kamperman AM, Boyce P, Bergink V. Guidelines on treatment of perinatal depression with antidepressants: an international review. Aust N Z J Psychiatry. 2018;52:320\u20137.","journal-title":"Aust N Z J Psychiatry"},{"key":"1574_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.therap.2023.11.002","volume":"79","author":"M Louchet","year":"2024","unstructured":"Louchet M, Tisseyre M, Kaguelidou F, Treluyer J-M, Pr\u00e9ta L-H, Chouchana L. Drug-induced fetal and offspring disorders, beyond birth defects. Therapie. 2024;79:205\u201319.","journal-title":"Therapie"},{"key":"1574_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.295.5.499","volume":"295","author":"LS Cohen","year":"2006","unstructured":"Cohen LS. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499.","journal-title":"JAMA"},{"key":"1574_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160","volume":"13","author":"G Pariente","year":"2016","unstructured":"Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016;13:e1002160.","journal-title":"PLoS Med"},{"key":"1574_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2174\/1381612825666190319102812","volume":"25","author":"N Bouazza","year":"2019","unstructured":"Bouazza N, Foissac F, Hirt D, Urien S, Benaboud S, Lui G, et al. Methodological approaches to evaluate fetal drug exposure. Curr Pharm Des. 2019;25:496\u2013504.","journal-title":"Curr Pharm Des"},{"key":"1574_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.940644","volume":"9","author":"P Coppola","year":"2022","unstructured":"Coppola P, Kerwash E, Nooney J, Omran A, Cole S. Pharmacokinetic data in pregnancy: a review of available literature data and important considerations in collecting clinical data. Front Med (Lausanne). 2022;9:940644.","journal-title":"Front Med (Lausanne)"},{"key":"1574_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/clpt.2011.66","volume":"90","author":"JR Hutson","year":"2011","unstructured":"Hutson JR, Garcia-Bournissen F, Davis A, Koren G. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther. 2011;90:67\u201376.","journal-title":"Clin Pharmacol Ther"},{"key":"1574_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/psp4.12274","volume":"7","author":"AB Ke","year":"2018","unstructured":"Ke AB, Greupink R, Abduljalil K. Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations. CPT Pharmacom Syst Pharma. 2018;7:103\u201310.","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"1574_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10928-020-09698-w","volume":"47","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Badhan RKS. Drug dosing during pregnancy\u2014opportunities for physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2020;47:319\u201340.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1574_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bcp.12815","volume":"81","author":"M De Sousa Mendes","year":"2016","unstructured":"De Sousa Mendes M, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, et al. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol. 2016;81:646\u201357.","journal-title":"Br J Clin Pharmacol"},{"key":"1574_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","volume":"51","author":"K Abduljalil","year":"2012","unstructured":"Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51:365\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"1574_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","volume":"47","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Pansari A, Jamei M. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. J Pharmacokinet Pharmacodyn. 2020;47:361\u201383.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1574_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.840710","volume":"10","author":"K Abduljalil","year":"2022","unstructured":"Abduljalil K, Gardner I, Jamei M. Application of a physiologically based pharmacokinetic approach to predict theophylline pharmacokinetics using virtual non-pregnant, pregnant, fetal, breast-feeding, and neonatal populations. Front Pediatr. 2022;10:840710.","journal-title":"Front Pediatr"},{"key":"1574_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40262-018-0685-y","volume":"58","author":"K Abduljalil","year":"2019","unstructured":"Abduljalil K, Jamei M, Johnson TN. Fetal physiologically based pharmacokinetic models: systems information on the growth and composition of fetal organs. Clin Pharmacokinet. 2019;58:235\u201362.","journal-title":"Clin Pharmacokinet"},{"key":"1574_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40262-019-00836-3","volume":"59","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Jamei M, Johnson TN. Fetal physiologically based pharmacokinetic models: systems information on fetal blood components and binding proteins. Clin Pharmacokinet. 2020;59:629\u201342.","journal-title":"Clin Pharmacokinet"},{"key":"1574_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40262-020-00973-0","volume":"60","author":"K Abduljalil","year":"2021","unstructured":"Abduljalil K, Pan X, Clayton R, Johnson TN, Jamei M. Fetal physiologically based pharmacokinetic models: systems information on fetal cardiac output and its distribution to different organs during development. Clin Pharmacokinet. 2021;60:741\u201357.","journal-title":"Clin Pharmacokinet"},{"key":"1574_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.placenta.2025.06.015","volume":"168","author":"L-H Pr\u00e9ta","year":"2025","unstructured":"Pr\u00e9ta L-H, Bouazza N, Foissac F, Froelicher L, Urien S, Dauvilliers A, et al. Comparison of human transplacental transfer of escitalopram, sertraline and paroxetine: an ex vivo cotyledon perfusion study. Placenta. 2025;168:150\u20138.","journal-title":"Placenta"},{"key":"1574_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2022.105471","volume":"85","author":"D Roelofsen","year":"2022","unstructured":"Roelofsen D, Van Hove H, Bukkems V, Russel F, Eliesen G, Greupink R. Predicting fetal exposure of crizotinib during pregnancy: combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling. Toxicol In Vitro. 2022;85:105471.","journal-title":"Toxicol In Vitro"},{"key":"1574_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25231","volume":"10","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Guo Z, Tan Y, Li L, Wang Z, Wen Y, et al. Population pharmacokinetic approach to guide personalized sertraline treatment in Chinese patients. Heliyon. 2024;10:e25231.","journal-title":"Heliyon"},{"key":"1574_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11:225\u201337.","journal-title":"AAPS J"},{"key":"1574_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/psp4.12110","volume":"5","author":"I Templeton","year":"2016","unstructured":"Templeton I, Chen Y, Mao J, Lin J, Yu H, Peters S, et al. Quantitative prediction of drug-drug interactions involving inhibitory metabolites in drug development: how can physiologically based pharmacokinetic modeling help? CPT Pharmacomet Syst Pharmacol. 2016;5:505\u201315.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1574_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259\u201376.","journal-title":"J Pharm Sci"},{"key":"1574_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1208\/s12248-020-0418-7","volume":"22","author":"E Yau","year":"2020","unstructured":"Yau E, Olivares-Morales A, Gertz M, Parrott N, Darwich AS, Aarons L, et al. Global sensitivity analysis of the Rodgers and Rowland model for prediction of tissue: plasma partitioning coefficients: assessment of the key physiological and physicochemical factors that determine small-molecule tissue distribution. AAPS J. 2020;22:41.","journal-title":"AAPS J"},{"key":"1574_CR30","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1124\/dmd.114.061523","volume":"43","author":"B Steere","year":"2015","unstructured":"Steere B, Baker JAR, Hall SD, Guo Y. Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model. Drug Metab Dispos. 2015;43:870\u201383.","journal-title":"Drug Metab Dispos"},{"key":"1574_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105061","volume":"139","author":"L Zhou","year":"2019","unstructured":"Zhou L, Sharma P, Yeo KR, Higashimori M, Xu H, Al-Huniti N, et al. Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling. Eur J Pharm Sci. 2019;139:105061.","journal-title":"Eur J Pharm Sci"},{"key":"1574_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1124\/dmd.109.030551","volume":"38","author":"J Jornil","year":"2010","unstructured":"Jornil J, Jensen KG, Larsen F, Linnet K. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010;38:376\u201385.","journal-title":"Drug Metab Dispos"},{"key":"1574_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement H, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"1574_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-020-00157-3","volume":"6","author":"B George","year":"2020","unstructured":"George B, Lumen A, Nguyen C, Wesley B, Wang J, Beitz J, et al. Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. NPJ Syst Biol Appl. 2020;6:36.","journal-title":"NPJ Syst Biol Appl"},{"key":"1574_CR35","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4088\/JCP.v69n0419","volume":"69","author":"DK Sit","year":"2008","unstructured":"Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry. 2008;69:652\u20138.","journal-title":"J Clin Psychiatry"},{"key":"1574_CR36","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/JCP.0b013e31818d2048","volume":"28","author":"MP Freeman","year":"2008","unstructured":"Freeman MP, Nolan PE, Davis MF, Anthony M, Fried K, Fankhauser M, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008;28:646\u201353.","journal-title":"J Clin Psychopharmacol"},{"key":"1574_CR37","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00228-021-03122-z","volume":"77","author":"E Heinonen","year":"2021","unstructured":"Heinonen E, Blennow M, Blomdahl-Wetterholm M, Hovstadius M, Nasiell J, Pohanka A, et al. Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low. Eur J Clin Pharmacol. 2021;77:1323\u201331.","journal-title":"Eur J Clin Pharmacol"},{"key":"1574_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181082","volume":"12","author":"AA Westin","year":"2017","unstructured":"Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: changes in drug disposition. PLoS ONE. 2017;12:e0181082 (Homberg J, editor.).","journal-title":"PLoS ONE"},{"key":"1574_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","volume":"29","author":"C Sanchez","year":"2014","unstructured":"Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol. 2014;29:185\u201396.","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 1","key":"1574_CR40","first-page":"S115","volume":"62","author":"L Zheng","year":"2022","unstructured":"Zheng L, Yang H, Dallmann A. Antidepressants and antipsychotics in human pregnancy: transfer across the placenta and opportunities for modeling studies. J Clin Pharmacol. 2022;62(Suppl 1):S115\u201328.","journal-title":"J Clin Pharmacol"},{"key":"1574_CR41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.4088\/JCP.10m06461","volume":"72","author":"D Sit","year":"2011","unstructured":"Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatry. 2011;72:994\u20131001.","journal-title":"J Clin Psychiatry"},{"key":"1574_CR42","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S0006-3223(00)00958-6","volume":"48","author":"A Hostetter","year":"2000","unstructured":"Hostetter A, Ritchie JC, Stowe ZN. Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women. Biol Psychiatry. 2000;48:1032\u20134.","journal-title":"Biol Psychiatry"},{"key":"1574_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1055\/s-0028-1103296","volume":"42","author":"J Rampono","year":"2009","unstructured":"Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42:95\u2013100.","journal-title":"Pharmacopsychiatry"},{"key":"1574_CR44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1017\/S1461145704004286","volume":"7","author":"J Rampono","year":"2004","unstructured":"Rampono J, Proud S, Hackett LP, Kristensen JH, Ilett KF. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharm. 2004;7:329\u201334.","journal-title":"Int J Neuropsychopharm"},{"key":"1574_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/FTD.0000000000000370","volume":"39","author":"L Pogliani","year":"2017","unstructured":"Pogliani L, Falvella FS, Cattaneo D, Pileri P, Moscatiello AF, Cheli S, et al. Pharmacokinetics and pharmacogenetics of selective serotonin reuptake inhibitors during pregnancy: an observational study. Ther Drug Monit. 2017;39:197\u2013201.","journal-title":"Ther Drug Monit"},{"key":"1574_CR46","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1176\/appi.ajp.160.5.993","volume":"160","author":"V Hendrick","year":"2003","unstructured":"Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. AJP. 2003;160:993\u20136.","journal-title":"AJP"},{"key":"1574_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2017.01.019","volume":"212","author":"M Paulzen","year":"2017","unstructured":"Paulzen M, Goecke TW, Stickeler E, Gr\u00fcnder G, Schoretsanitis G. Sertraline in pregnancy\u2014therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. J Affect Disord. 2017;212:1\u20136.","journal-title":"J Affect Disord"},{"key":"1574_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.833217","volume":"13","author":"EA Poweleit","year":"2022","unstructured":"Poweleit EA, Cinibulk MA, Novotny SA, Wagner-Schuman M, Ramsey LB, Strawn JR. Selective serotonin reuptake inhibitor pharmacokinetics during pregnancy: clinical and research implications. Front Pharmacol. 2022;13:833217.","journal-title":"Front Pharmacol"},{"key":"1574_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3642","author":"CS Stika","year":"2025","unstructured":"Stika CS, Avram MJ, George AL, Yang A, Ciolino JD, Jeong H, et al. Changes in S-citalopram plasma concentrations across pregnancy and postpartum. Clin Pharma Ther. 2025. https:\/\/doi.org\/10.1002\/cpt.3642.","journal-title":"Clin Pharma Ther"},{"key":"1574_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2772","author":"A Colombo","year":"2021","unstructured":"Colombo A, Giordano F, Giorgetti F, Di Bernardo I, Bosi MF, Varinelli A, et al. Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affective disorders. Hum Psychopharmacol Clin Exp. 2021. https:\/\/doi.org\/10.1002\/hup.2772.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1574_CR51","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2165\/11318050-000000000-00000","volume":"48","author":"FFT Ververs","year":"2009","unstructured":"Ververs FFT, Voorbij HAM, Zwarts P, Belitser SV, Egberts TCG, Visser GHA, et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet. 2009;48:677\u201383.","journal-title":"Clin Pharmacokinet"},{"key":"1574_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2282","author":"M Yue","year":"2023","unstructured":"Yue M, Kus L, Katta S, Su I, Li L, Haas DM, et al. Pharmacokinetics of Antidepressants in Pregnancy. J Clin Pharma. 2023. https:\/\/doi.org\/10.1002\/jcph.2282.","journal-title":"J Clin Pharma"},{"key":"1574_CR53","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/jphp.13281","volume":"72","author":"A Almurjan","year":"2020","unstructured":"Almurjan A, Macfarlane H, Badhan RKS. Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study. J Pharm Pharmacol. 2020;72:1049\u201360.","journal-title":"J Pharm Pharmacol"},{"key":"1574_CR54","doi-asserted-by":"publisher","first-page":"231","DOI":"10.31887\/DCNS.2005.7.3\/pbaumann","volume":"7","author":"P Baumann","year":"2005","unstructured":"Baumann P, Ulrich S, Eckermann G, Gerlach M, Kuss H-J, Laux G, et al. The AGNP-TDM expert group consensus guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci. 2005;7:231\u201347.","journal-title":"Dialogues Clin Neurosci"},{"key":"1574_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2011.10.005","volume":"197","author":"A Bonnin","year":"2011","unstructured":"Bonnin A, Levitt P. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience. 2011;197:1\u20137.","journal-title":"Neuroscience"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01574-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01574-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01574-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:01:48Z","timestamp":1766059308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01574-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1574"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01574-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by a 3-years PhD grant from the Fondation pour la Recherche M\u00e9dicale, grant number # FDM202206015346, to LH. Pr\u00e9ta. This work was also supported by a GIS-FC3R funding managed by the Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM), grant number # 22FC3R-018, project leader: Dr. F. Foissac. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"L.-H.P., N.B., F.F., L.F., S.U., V.B., S.B., J.-M.T., and G.L. declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are included in this article and in its supplementary material files, which can be found in the online version of this article. Data are also available upon reasonable request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Concept and design: L.-H.P., N.B., F.F., V.B., S.B., J.-M.T., and G.L.; analysis and interpretation of data: L.-H.P., N.B., F.F., L.F., S.U., S.B., J.-M.T., and G.L.; drafting of the manuscript: L.-H.P., N.B., F.F., S.B., S.U., and G.L. Critical revision of the manuscript: All authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}